{"commentary":{"count":26,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":12,"youtube":9,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05879926\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"OFSET","nct_id":"NCT05879926","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ofset-nct05879926. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"OFSET","arms":[{"description":"Aromatase inhibitor co-administered with a GnRH agonist (gonadotropin releasing hormone) for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.","label":"Arm 1: Ovarian Function Suppression + Aromatase Inhibitor","type":"ACTIVE_COMPARATOR"},{"description":"Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.","label":"Arm 2 Adjuvant Chemotherapy + Ovarian Function Suppression + Aromatase Inhibitor","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2034-07","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":3960,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ovarian Function Suppression + Aromatase Inhibitor","type":"DRUG"},{"name":"Adjuvant Chemotherapy + Ovarian Function Suppression","type":"DRUG"}],"last_update":"2026-09-02","lead_sponsor":"NRG Oncology","official_title":"A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Invasive breast cancer-free survival (IBCFS)","timeFrame":"Time from randomization for duration of trial, 11 years"}],"references":[],"start_date":{"date":"2023-10-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","url":"https://clinicaltrials.gov/study/NCT05879926"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ofset-nct05879926"}